Tech Company Financing Transactions
T-Therapeutics Funding Round
Advent Life Sciences, British Business Bank and BGF Ventures invested in a $133 million Series B funding round for T-Therapeutics. The round was announced on 11/5/2026.
Transaction Overview
Company Name
Announced On
11/5/2026
Transaction Type
Venture Equity
Amount
$133,000,000
Round
Series B
Investors
Proceeds Purpose
The company intends to use the funds to support entry into the clinic and the generation of clinical data for its two lead TCR-CD3 bispecific programmes in oncology and autoimmune diseases.
Company Information
Company Status
Private & Independent
Industry
Biopharmaceutical
Mailing Address
Suite 1 Riverside 3 Granta Park
Cambridge, England, CB21 6AD
UK
Cambridge, England, CB21 6AD
UK
Phone
Undisclosed
Website
Email Address
Overview
T-Therapeutics is developing a pipeline of first-in-class drugs that will become transformative medicines, reshaping the clinical landscape for patients with cancer or autoimmune diseases.
Profile
Social Media
Company News
Facebook
YouTube
Management Team
Title
Name
Email & Social
Chief Executive Officer
Allan Bradley
Chief Financial Officer
Alison Lloyd
Browse more venture capital transactions:
Prev: 11/5/2026: Laza Medical venture capital transaction
Next: 11/5/2026: Anaheim Bio venture capital transaction
Share this article
Where The Data Comes From
Our team works diligently to report on every notable VC transaction. VC investment data records reported here are sourced from news reports and company announcements. The information comes to us via our partnership with VentureDeal.com, an affiliated venture.
Additional Resources for Entrepreneurs